All In Biotech

Drug Trial Radar · NCT01253642

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy

Last checked: Nov 20, 2026Latest source record: Oct 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

11

Actual

Start

Jul 12, 2010

Primary completion

Sep 15, 2016

Study completion Sep 15, 2017

Sponsor

Lead sponsor
OHSU Knight Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation
First posted
Dec 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well giving phenelzine sulfate together with docetaxel works in treating patients with prostate cancer that is growing, spreading, or getting worse after first-line therapy with docetaxel. Phenelzine sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Phenelzine sulfate may also help docetaxel work better by making tumor cells more sensitive to the drug. Giving phenelzine sulfate together with docetaxel may kill more tumor cells.

Conditions

  • Hormone-Resistant Prostate Cancer
  • Metastatic Prostatic Adenocarcinoma
  • Prostate Adenocarcinoma
  • Recurrent Prostate Carcinoma

Interventions

  • Biopsy of ProstateProcedure

    Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy

  • DocetaxelDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Phenelzine SulfateDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Who Experience a PSA (Prostate-Specific Antigen) Decline of at Least 30%Time frame: Within 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • OHSU Knight Cancer Institute

    Portland, Oregon

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.